S'abonner

Cystatin M/E, Cathepsin V and Asparaginyl Endopeptidase: New actors of the proteolytic balance in lung fibrosis - 08/04/25

Doi : 10.1016/j.rmr.2025.02.081 
B. Rigoux 1, , A. David 1, R. Allouche 1, L. Vanderlynden 1, F. Lecaille 1, 2, S. Marchand-Adam 1, 3, G. Lalmanach 1, 2, A. Saidi 1
1 INSERM, UMR1100, Research Center for Respiratory Diseases (CEPR), Team “Proteolytic enzymes and their pharmacological targeting in lung diseases”, Faculty of Medicine, University of Tours, Tours, France 
2 Department of Biochemistry, Faculty of Sciences and Techniques, University of Tours, Tours, France 
3 The University Hospital Center of Tours (CHRU Tours), Pulmonology Department, Tours, France 

Auteur correspondant.

Résumé

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic disease with unknown etiology, characterized by progressive and irreversible fibrous thickening in the interstitial spaces of the lung. Alterations in alveolar epithelia induce the TGF-β1-dependent differentiation and proliferation of fibroblasts into myofibroblasts. Extracellular matrix (ECM) overproduction by myofibroblasts causes a dysregulated remodeling in fibrotic foci, which is closely associated with an altered protease/antiprotease balance [1]. Among proteases involved, some cysteine cathepsins are potent collagenases and elastases which participate in ECM remodeling. During IPF, the cathepsin/cystatin (i.e. endogenous cathepsin inhibitors) balance is impaired in favor of cystatins. The secretion of human Cystatin C (CysC) is upregulated during myodifferentiation, promoting collagen I deposition [2]. In addition, expression levels of both fibronectin and elastin are altered during fibrogenesis. Accordingly, this led us to investigate the involvement of Cathepsin V (CatV, the most potent human elastase) [3], Asparaginyl endopeptidase (AEP) (a.k.a. Legumain (LGMN), participate in extracellular matrix degradation) [4] and of Cystatin M/E (CysM) (a dual tight-binding inhibitor of both enzymes) [5], in the differentiation of human lung fibroblasts.

Methods

Characterization of CysC, CysM, CatV and AEP was conducted by immunochemical analysis of control and IPF bronchoalveolar lavage fluid (BALF) and lung biopsies. CCD-19Lu human lung fibroblasts were used as a model of TGF-β1-dependent myodifferentiation to study the regulation of these proteases and cystatins during pulmonary fibrosis. SiRNAs targeting the proteins of interest and the effects on ECM were evaluated as previously. Also, kinetic assays were performed.

Results

We observed that CysC and CysM are oversecreted in IPF patients BALF. Similar results were observed in supernatants of TGF-β1-differentiated human lung fibroblasts. Furthermore, silencing of CatV and AEP increased the expression levels of ECM proteins, elastin and fibronectin, respectively.

Conclusion

Our data support that CysC and CysM are key molecular players involved in the TGF-β1-dependent myofibrogenesis. Secreted forms could impair both fibronectin degradation and elastinolytic activities of extracellular cysteine proteases. Results obtained from IPF lung biopsies further confirmed this imbalance between protease and cystatins. Since, these proteases are involved in the ECM remodeling, we suggest that this alteration of protease/antiprotease balance may subsequently promote fibrotic phenotype found in IPF.

Le texte complet de cet article est disponible en PDF.

Plan


© 2025  Publié par Elsevier Masson SAS.
Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 42 - N° 4

P. 222 - avril 2025 Retour au numéro
Article précédent Article précédent
  • Is the Cx43-specific inhibitor 43Gap26 a relevant therapeutic target in BPD and BPD-PH induced by hyperoxia?
  • C.M. Pilard, L. Gassiat, C. Cardouat, I. Gauthereau, P. Robillard, E. Dumas-de-la-Roque, F. Sauvestre, F. Pelluard, S. Berenguer, L. Sentilhes, F. Coatleven, M. Vincienne, R. Marthan, P. Berger, V. Freund-Michel, C. Guibert
| Article suivant Article suivant
  • Caractérisation de l’impact moléculaire et cellulaire de variants de PARN associés à la fibrose pulmonaire
  • K. Kunene, M. Jaillet, I. Ba, C. Brasseur, A. Guyard, A. Cazes, C. Kannengiesser, A. Mailleux, P. Revy, R. Borie, B. Crestani, Q. Philippot

Déjà abonné à cette revue ?